IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 1,083,025 shares changed hands during trading, an increase of 25% from the previous session's volume of 867,972 shares.The stock last traded at $25.75 and had previously closed at $25.16.
Analyst Ratings Changes
A number of research analysts have issued reports on IDYA shares. Wedbush reissued an "outperform" rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Oppenheimer reissued an "outperform" rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Leerink Partners cut shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $41.00 to $27.00 in a report on Tuesday, November 5th. Stifel Nicolaus upped their target price on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a "buy" rating in a research report on Tuesday, September 10th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $53.67.
Check Out Our Latest Stock Report on IDYA
IDEAYA Biosciences Price Performance
The stock's 50 day simple moving average is $27.38 and its two-hundred day simple moving average is $33.18. The company has a market capitalization of $2.25 billion, a P/E ratio of -11.16 and a beta of 0.79.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter in the prior year, the business posted ($0.46) earnings per share. As a group, equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.
Hedge Funds Weigh In On IDEAYA Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV boosted its position in shares of IDEAYA Biosciences by 29.1% during the third quarter. KBC Group NV now owns 2,274 shares of the company's stock worth $72,000 after purchasing an additional 513 shares in the last quarter. Amalgamated Bank raised its holdings in shares of IDEAYA Biosciences by 22.9% in the third quarter. Amalgamated Bank now owns 2,840 shares of the company's stock valued at $90,000 after purchasing an additional 530 shares during the last quarter. US Bancorp DE raised its holdings in IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after acquiring an additional 689 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of IDEAYA Biosciences by 35.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company's stock valued at $94,000 after buying an additional 796 shares during the last quarter. Finally, Allworth Financial LP increased its holdings in IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after buying an additional 800 shares during the last quarter. Institutional investors own 98.29% of the company's stock.
IDEAYA Biosciences Company Profile
(
Get Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Recommended Stories
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
